TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32272914

Group type: EXPERIMENTAL
Intervention: Magnesium citrate (300 mg magnesium citrate daily)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo capsule (daily)
Number of subjects: 318
Study: 34151502

Group type: EXPERIMENTAL
Intervention: SciMoCa (secondary Monte Carlo dose calculation)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MLC shift errors
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Plausibility check of TPS Monaco vs. BP measurement and SciMoCa vs. BP measurement
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SciMoCa
Number of subjects: 30
Study: 32666905

Group type: EXPERIMENTAL
Intervention: Electronic treatment register used in the DeWorm3 Project for mass drug administration.
Number of subjects: 0
Study: 35852595

Group type: EXPERIMENTAL
Intervention: AIUSP
Number of subjects: 400

Group type: COMPARATOR
Intervention: TRUS-SB
Number of subjects: 400

Group type: COMPARATOR
Intervention: mpMRI
Number of subjects: 400
Study: 33683419

Group type: EXPERIMENTAL
Intervention: Melatonin supplementation
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (COS protocol only)
Number of subjects: 90
Study: 32683755

Group type: EXPERIMENTAL
Intervention: cfDNA group
Number of subjects: 40

Group type: COMPARATOR
Intervention: FTCS group
Number of subjects: 40
Study: 35042751

Group type: EXPERIMENTAL
Intervention: Efpeglenatide (4 mg or 6 mg once weekly, 6 mg or 8 mg once every 2 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Efpeglenatide
Number of subjects: 0
Study: 32001530

Group type: EXPERIMENTAL
Intervention: Intensive vincristine dosing
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplantation (HCT)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: MRD <0.1% at the end of Induction-1
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: MRD ≥0.1% at the end of Induction-1
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Early iCNS relapse
Number of subjects: 275
Study: 33940113

Group type: EXPERIMENTAL
Intervention: EvoCit (heparin-grafted dialyzer with citrate-enriched dialysate)
Number of subjects: 26

Group type: COMPARATOR
Intervention: EvoHep (heparin-grafted dialyzer with systemic heparin)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: EvoCit
Number of subjects: 26

Group type: COMPARATOR
Intervention: EvoHep
Number of subjects: 26
Study: 32753452

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 600
Study: 36423489

Group type: EXPERIMENTAL
Intervention: High-Intensity Resistance Training (HIRT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 38
Study: 33586911

Group type: EXPERIMENTAL
Intervention: Financial incentives for home-based HIV testing and linkage to care (R50 food voucher each)
Number of subjects: 13838

Group type: EXPERIMENTAL
Intervention: Male-targeted HIV-specific decision support application (EPIC-HIV)
Number of subjects: 13838

Group type: EXPERIMENTAL
Intervention: Both financial incentives and EPIC-HIV application
Number of subjects: 13838

Group type: COMPARATOR
Intervention: Standard of care (SoC)
Number of subjects: 13838
Study: 35149238

Group type: EXPERIMENTAL
Intervention: Topical application of hyperoxygenated fatty acids (HOFA) solution
Number of subjects: 103

Group type: COMPARATOR
Intervention: Saline physiological solution (non-HOFA)
Number of subjects: 103
Study: 33827787

Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 32873573

Group type: EXPERIMENTAL
Intervention: Ex vivo-activated NK cells (4 cycles activated with TKD/IL2) after RCT
Number of subjects: 0

Group type: COMPARATOR
Intervention: RCT alone
Number of subjects: 0
Study: 35477085

Group type: EXPERIMENTAL
Intervention: Stress management training (SMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34856148

Group type: EXPERIMENTAL
Intervention: Maintenance olaparib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33413511

Group type: EXPERIMENTAL
Intervention: TF-CBT
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: BASIS+TF-CBT
Number of subjects: 480

Group type: COMPARATOR
Intervention: Enhanced TAU
Number of subjects: 480

Group type: COMPARATOR
Intervention: Attention control plus TF-CBT
Number of subjects: 480
Study: 32077392

Group type: EXPERIMENTAL
Intervention: Olive/Soyabean lipid emulsion (O/S) at a dose of 0.8 g/kg per day for 7 days
Number of subjects: 19

Group type: COMPARATOR
Intervention: 100% Fish oil (FO) at a dose of 0.4 g/kg per day for 7 days
Number of subjects: 19
Study: 33449924

Group type: EXPERIMENTAL
Intervention: Annual school-based preventive chemotherapy with praziquantel (40 mg/kg) over four years
Number of subjects: 7410

Group type: EXPERIMENTAL
Intervention: Praziquantel treatment only in the first two years, followed by two years without treatment
Number of subjects: 7410

Group type: EXPERIMENTAL
Intervention: Praziquantel treatment in years 1 and 3 without treatment in-between
Number of subjects: 7410

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 7410
Study: 32414398

Group type: EXPERIMENTAL
Intervention: Ivermectin 3-monthly (150 µg/kg or 800 µg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ivermectin annually (150 µg/kg or 800 µg/kg)
Number of subjects: 0
Study: 35930126

Group type: EXPERIMENTAL
Intervention: Galcanezumab (GMB) 120 mg with 240 mg loading dose
Number of subjects: 462

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Galcanezumab (GMB)
Number of subjects: 462
Study: 32713467

Group type: EXPERIMENTAL
Intervention: Suprascapular nerve decompression
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (no suprascapular nerve decompression)
Number of subjects: 19
Study: 34939742

Group type: EXPERIMENTAL
Intervention: Indirect ophthalmoscopy with lid speculum (Sp)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Speculum free indirect ophthalmoscopy (SpF)
Number of subjects: 37
Study: 33953828

Group type: EXPERIMENTAL
Intervention: IL-37 serum level
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: IL-37 in the highest quartile (>405.3 pg/ml)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: IL-37/NIHSS
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: IL-37 in the highest quartile
Number of subjects: 310
Study: 32604401

Group type: EXPERIMENTAL
Intervention: Active prefrontal tDCS at 2 mA for 20 minutes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 33486528

Group type: EXPERIMENTAL
Intervention: Increased BMI (≥25 kg/m2, quartile 3-4)
Number of subjects: 10611

Group type: EXPERIMENTAL
Intervention: Increased WC (≥85 cm for females, quartile 3-4)
Number of subjects: 10611

Group type: EXPERIMENTAL
Intervention: Increased WC (≥84 cm for males, quartile 3-4)
Number of subjects: 10611

Group type: EXPERIMENTAL
Intervention: WC forced into the model with BMI simultaneously (<85 vs. ≥85 cm for females)
Number of subjects: 10611

Group type: EXPERIMENTAL
Intervention: WC forced into the model with BMI simultaneously (≥84 vs. <84 cm for males)
Number of subjects: 10611

Group type: EXPERIMENTAL
Intervention: BMI (≥25 vs. <25 kg/m2)
Number of subjects: 10611

Group type: EXPERIMENTAL
Intervention: Higher time-averaged on-treatment systolic blood pressure (median: <138.3 vs. ≥138.3 mmHg)
Number of subjects: 10611
Study: 35590169

Group type: EXPERIMENTAL
Intervention: Maternal vaginal gauze swabbed on CS-born babies
Number of subjects: 177

Group type: COMPARATOR
Intervention: Vaginal birth
Number of subjects: 177

Group type: COMPARATOR
Intervention: Non-pregnant women from the Human Microbiome Project (HMP) study
Number of subjects: 177
Study: 35847998

Group type: EXPERIMENTAL
Intervention: 2-weekly docetaxel 50 mg/m2
Number of subjects: 336

Group type: COMPARATOR
Intervention: 3-weekly docetaxel 75 mg/m2
Number of subjects: 336
Study: 34280657

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 2376

Group type: EXPERIMENTAL
Intervention: Neuromuscular blockade
Number of subjects: 2376

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 2376

Group type: EXPERIMENTAL
Intervention: Tidal volume index
Number of subjects: 2376

Group type: EXPERIMENTAL
Intervention: Plateau pressures
Number of subjects: 2376

Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressures
Number of subjects: 2376

Group type: EXPERIMENTAL
Intervention: Volume-controlled ventilation
Number of subjects: 2376

Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 2376
Study: 34121334

Group type: EXPERIMENTAL
Intervention: Petrolatum applied twice daily for 8 weeks
Number of subjects: 12
Study: 33538987

Group type: EXPERIMENTAL
Intervention: Low vitamin D (below the median) and increased Hcy
Number of subjects: 3150

Group type: COMPARATOR
Intervention: Vitamin D levels above the median
Number of subjects: 3150
Study: 33345910

Group type: EXPERIMENTAL
Intervention: 60 mg aspirin daily (Low-Risk Aspirin trial)
Number of subjects: 5674

Group type: EXPERIMENTAL
Intervention: 60 mg aspirin daily (High-Risk Aspirin trial)
Number of subjects: 5674

Group type: COMPARATOR
Intervention: Placebo (Low-Risk Aspirin trial)
Number of subjects: 5674

Group type: COMPARATOR
Intervention: Placebo (High-Risk Aspirin trial)
Number of subjects: 5674
Study: 34477931

Group type: EXPERIMENTAL
Intervention: Endurance standard training
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Endurance polarized training
Number of subjects: 21
Study: 34378669

Group type: EXPERIMENTAL
Intervention: Early Recovery After Surgery (ERAS) protocol performed by speech therapists, involving specific motricity exercises and lymphatic drainage
Number of subjects: 19

Group type: COMPARATOR
Intervention: Rehabilitation protocol involving active and passive mouth opening exercises
Number of subjects: 19
Study: 36151869

Group type: EXPERIMENTAL
Intervention: gantenerumab SC (n=52)
Number of subjects: 142

Group type: COMPARATOR
Intervention: solanezumab IV (n=50)
Number of subjects: 142

Group type: COMPARATOR
Intervention: placebo (n=40)
Number of subjects: 142
Study: 32661104

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care service (intervention group)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Standard medical care (control group)
Number of subjects: 123
Study: 32069120

Group type: EXPERIMENTAL
Intervention: HUS+/VRT+
Number of subjects: 162

Group type: COMPARATOR
Intervention: HUS+/VRT-
Number of subjects: 162

Group type: COMPARATOR
Intervention: HUS-/VRT+
Number of subjects: 162

Group type: COMPARATOR
Intervention: HUS-/VRT-
Number of subjects: 162

Group type: COMPARATOR
Intervention: HUS-/VRT+ (abnormal SVV)
Number of subjects: 162

Group type: COMPARATOR
Intervention: HUS+/VRT- (normal SVV)
Number of subjects: 162
Study: 35442482

Group type: EXPERIMENTAL
Intervention: T‐VAM
Number of subjects: 22

Group type: COMPARATOR
Intervention: 20‐m MST
Number of subjects: 22
Study: 34510965

Group type: EXPERIMENTAL
Intervention: Test-coached participants (m=4.58-5.68, SD=2.2-3)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Test-coached participants (m=3.8-5.6, SD=1.51-2.2)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Online simulators
Number of subjects: 115
Study: 35593744

Group type: EXPERIMENTAL
Intervention: Verinurad + Allopurinol (24 mg verinurad + 300 mg allopurinol)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Verinurad + Allopurinol (12 mg verinurad + 300 mg allopurinol)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Verinurad (12 mg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 32980558

Group type: EXPERIMENTAL
Intervention: Laser acupuncture (power 50 mW, 785 nm, 1 Joule, 40 seconds) applied three times a week for 12 sessions.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo laser acupuncture on the same points.
Number of subjects: 60
Study: 35087602

Group type: EXPERIMENTAL
Intervention: Somatostatin combined with transanal intestinal obstruction decompression catheter
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 30
Study: 35470026

Group type: EXPERIMENTAL
Intervention: Prebiotic and probiotic intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 35365457

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided stellate ganglion block (SGB) with 7 mL 0.5% ropivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 60
Study: 34013326

Group type: EXPERIMENTAL
Intervention: Supportive educational intervention (group-based sessions including psychological coping strategies, familiarity with NCU environment, equipment, personnel and procedures)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 41
Study: 32513245

Group type: EXPERIMENTAL
Intervention: Laser group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-laser group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-leakage group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-laser group (with leakage)
Number of subjects: 0
Study: 35079071

Group type: EXPERIMENTAL
Intervention: TM+V (vibration applied with 5.2±0.5 g-forces, 102.2±2.6 Hertz for 3 min)
Number of subjects: 46

Group type: COMPARATOR
Intervention: TM (non-vibration)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: TM+V and TM
Number of subjects: 46
Study: 35963534

Group type: EXPERIMENTAL
Intervention: Digital Images (DI)
Number of subjects: 640
Study: 34176274

Group type: EXPERIMENTAL
Intervention: Dairy products naturally enriched with selenium and omega-3 polyunsaturated fatty acids
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional dairy
Number of subjects: 46
Study: 35767699

Group type: EXPERIMENTAL
Intervention: Aerobic cycling exercise (1 h at 70%-75% V̇o2peak)
Number of subjects: 8

Group type: COMPARATOR
Intervention: High-glucose mixed-nutrient meal (1.1 g glucose/kg body wt)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Prior exercise with high-glucose meal ingestion 3-h postexercise
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Prior exercise with high-glucose meal ingestion 24-h postexercise
Number of subjects: 8
Study: 32865464

Group type: EXPERIMENTAL
Intervention: SRP coupled to diode laser (980 nm) protocol
Number of subjects: 160

Group type: COMPARATOR
Intervention: SRP alone (Control group)
Number of subjects: 160
Study: 35428992

Group type: EXPERIMENTAL
Intervention: 100 mg daily for 3 days
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: 100 mg thrice daily for 5 days
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: 300 mg thrice daily for 3 days
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: 300 mg thrice daily for 5 days
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: 500 mg thrice daily for 5 days
Number of subjects: 520

Group type: COMPARATOR
Intervention: 100 mg thrice daily for 3 days
Number of subjects: 520
Study: 33753352

Group type: EXPERIMENTAL
Intervention: High-dose 24-hour infusion of tranexamic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36134834

Group type: EXPERIMENTAL
Intervention: Statin therapy (suboptimal responders)
Number of subjects: 1029

Group type: EXPERIMENTAL
Intervention: Statin therapy (suboptimal responders with LDL < 55 mg/dL)
Number of subjects: 1029
Study: 34568986

Group type: EXPERIMENTAL
Intervention: OMFSs analyzing XR1
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Orthodontists analyzing XR1
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Orthodontists analyzing XR1 + XR2
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: OMFSs analyzing XR1 + XR2
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: OMFSs analyzing XR1 for impacted L3Ms
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Orthodontists analyzing XR1 for impacted L3Ms
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: OMFSs analyzing XR1 + XR2 for impacted L3Ms
Number of subjects: 34
Study: 35800293

Group type: EXPERIMENTAL
Intervention: Capecitabine + Ra223
Number of subjects: 34

Group type: COMPARATOR
Intervention: Capecitabine alone
Number of subjects: 34
Study: 33234598

Group type: EXPERIMENTAL
Intervention: Informed consent group
Number of subjects: 813

Group type: COMPARATOR
Intervention: Research without prior consent group
Number of subjects: 813
Study: 34429396

Group type: EXPERIMENTAL
Intervention: Propranolol (single dose)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 32569120

Group type: EXPERIMENTAL
Intervention: LOW load (15RM)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: MOD load (10RM)
Number of subjects: 27
Study: 33620615

Group type: EXPERIMENTAL
Intervention: Conization before radical hysterectomy
Number of subjects: 332

Group type: COMPARATOR
Intervention: Control group (no conization before radical hysterectomy)
Number of subjects: 332
Study: 33460320

Group type: EXPERIMENTAL
Intervention: Isradipine 5-mg twice daily
Number of subjects: 170
Study: 34759543

Group type: EXPERIMENTAL
Intervention: LMA removal at awake (Group A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: LMA removal at MAC =0.4 (Group B)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: LMA removal at MAC of 0.6 (Group C)
Number of subjects: 90
Study: 32077728

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 81)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Control group (n = 79)
Number of subjects: 238
Study: 33906043

Group type: EXPERIMENTAL
Intervention: Aquatic exercise (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 40
Study: 36385453

Group type: EXPERIMENTAL
Intervention: Emulsified isoflurane (30 mg/kg, 12% emulsified isoflurane)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Propofol (2 mg/kg, 0.8% propofol)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Emulsified isoflurane
Number of subjects: 416

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 416
Study: 32324308

Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 205

Group type: COMPARATOR
Intervention: Succinylcholine
Number of subjects: 205
Study: 34708996

Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg on day 1 followed by 90 mg twice daily on days 2 through 90)
Number of subjects: 6412

Group type: COMPARATOR
Intervention: Clopidogrel (300 mg on day 1 followed by 75 mg once daily on days 2 through 90)
Number of subjects: 6412

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 6412

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 6412
Study: 32451660

Group type: EXPERIMENTAL
Intervention: DHEA supplementation 25 mg/8 h for two consecutive cycles before induction of ovulation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no DHEA supplementation)
Number of subjects: 50
Study: 35319845

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with moxibustion on the affected side for 30 min once daily for 4 weeks.
Number of subjects: 96

Group type: COMPARATOR
Intervention: Acupuncture at Zusanli(ST36), Neixiyan(EX‐LE4), Heding(EX‐LE2) and Xuanzhong(GB39) for 30 min once daily for 4 weeks.
Number of subjects: 96
Study: 32231295

Group type: EXPERIMENTAL
Intervention: JNJ-67953964 (10 mg)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 32638239

Group type: EXPERIMENTAL
Intervention: Low-level laser treatment (LLLT)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 71
Study: 33052759

Group type: EXPERIMENTAL
Intervention: 3 years of sorafenib (400 mg twice per day orally, amended to 400 mg daily)
Number of subjects: 1711

Group type: COMPARATOR
Intervention: Placebo (3 years)
Number of subjects: 1711

Group type: EXPERIMENTAL
Intervention: 1 year of sorafenib followed by 2 years of placebo
Number of subjects: 1711

Group type: EXPERIMENTAL
Intervention: 3 years of sorafenib
Number of subjects: 1711

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1711

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 1711
Study: 36195339

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 22
Study: 34362410

Group type: EXPERIMENTAL
Intervention: multidisciplinary transition of care program and medications’ data transfer between inpatient and outpatient caregivers
Number of subjects: 346

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 346
Study: 33028254

Group type: EXPERIMENTAL
Intervention: Visual acuity measurement using pin-hole value
Number of subjects: 3400

Group type: EXPERIMENTAL
Intervention: Visual acuity measurement based on presenting visual acuity value
Number of subjects: 3400

Group type: EXPERIMENTAL
Intervention: Age and uncorrected refractive error
Number of subjects: 3400

Group type: EXPERIMENTAL
Intervention: Causes of visual impairment
Number of subjects: 3400
Study: 35843080

Group type: EXPERIMENTAL
Intervention: alectinib 300 mg
Number of subjects: 207

Group type: COMPARATOR
Intervention: crizotinib 250 mg
Number of subjects: 207
Study: 34089596

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (three 3-week cycles of CAPOX, four 2-week cycles of FOLFOX or FOLFORI) followed by neoadjuvant chemoradiotherapy and surgery
Number of subjects: 364

Group type: COMPARATOR
Intervention: Neoadjuvant chemoradiotherapy and surgery alone
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery
Number of subjects: 364
Study: 32268000

Group type: EXPERIMENTAL
Intervention: RO7020531 (150 mg, multiple ascending doses every other day)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: RO7020531 (various doses from 40 mg to 170 mg)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: RO7020531 (100 mg or above)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: RO7020531
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 34165604

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 107
Study: 34081021

Group type: EXPERIMENTAL
Intervention: Interactive web-based system via mobile phone
Number of subjects: 22
Study: 34343621

Group type: EXPERIMENTAL
Intervention: Effective decision support psychoeducation
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Decision support communication training
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Ottawa Decision Guide training
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Overall intervention
Number of subjects: 46